betaxolol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 356 63659-18-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betaxolol
  • (+/-)-Betaxolol
  • betaxolol hydrochloride
  • betaxolol HCl
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
  • Molecular weight: 307.43
  • Formula: C18H29NO3
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 50.72
  • ALOGS: -4.01
  • ROTB: 11
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.45 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 15 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.17 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 17 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,IKBKB,ITK,JAK3,MAP2K6,MAPK7,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1,ZAP70 26
kinase-selectivity-class CDK4,EIF2AK3 2
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.610 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.68
rat-kpuu-brain Rat brain Kpuu 0.476 % High 1

Approvals:

DateAgencyCompanyOrphan
Aug. 30, 1985 FDA ALCON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stevens-Johnson syndrome 86.90 25.30 36 3764 29340 90595307
Hyperaesthesia 84.17 25.30 27 3773 10675 90613972
Dental restoration failure 71.00 25.30 15 3785 1149 90623498
Limb injury 65.11 25.30 30 3770 31478 90593169
Nasal discharge discolouration 62.49 25.30 16 3784 2837 90621810
Angioplasty 61.98 25.30 14 3786 1463 90623184
Status epilepticus 58.75 25.30 24 3776 18850 90605797
Fall 57.89 25.30 85 3715 481725 90142922
Peripheral vascular disorder 53.75 25.30 17 3783 6414 90618233
Transient ischaemic attack 53.35 25.30 29 3771 43147 90581500
Phlebitis 51.34 25.30 17 3783 7413 90617234
Epigastric discomfort 51.03 25.30 17 3783 7551 90617096
Fungal infection 50.90 25.30 28 3772 42633 90582014
Crepitations 48.42 25.30 17 3783 8835 90615812
Catheter site pain 47.68 25.30 15 3785 5564 90619083
Choking 46.89 25.30 18 3782 12015 90612632
Haemorrhage 45.37 25.30 31 3769 69338 90555309
Encephalitis 44.62 25.30 17 3783 11117 90613530
Glaucoma 40.50 25.30 19 3781 20736 90603911
Sopor 40.34 25.30 20 3780 24624 90600023
Coma 39.49 25.30 29 3771 72603 90552044
Skin laceration 39.30 25.30 20 3780 26015 90598632
Urinary retention 37.54 25.30 22 3778 37722 90586925
Eye irritation 36.98 25.30 21 3779 33957 90590690
Pulmonary congestion 35.50 25.30 17 3783 19416 90605231
Middle insomnia 34.75 25.30 16 3784 16735 90607912
Sputum discoloured 34.72 25.30 17 3783 20374 90604273
Coronary artery disease 34.50 25.30 20 3780 33603 90591044
Bradycardia 33.69 25.30 28 3772 83819 90540828
Cardiac failure congestive 33.66 25.30 30 3770 98664 90525983
Panic attack 33.37 25.30 18 3782 26347 90598300
Poor venous access 32.41 25.30 16 3784 19511 90605136
Ischaemic stroke 30.49 25.30 16 3784 22150 90602497
Blindness 30.48 25.30 17 3783 26551 90598096
Vascular resistance systemic 30.09 25.30 4 3796 15 90624632
Acute myocardial infarction 28.68 25.30 18 3782 34872 90589775
Acquired haemophilia 28.41 25.30 7 3793 1062 90623585
Acute kidney injury 28.01 25.30 49 3751 320338 90304309
Pulmonary oedema 25.49 25.30 21 3779 62059 90562588

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypersensitivity 114.04 23.70 51 1204 72319 42547761
Cardiac disorder 94.99 23.70 40 1215 48892 42571188
Splenic rupture 48.76 23.70 11 1244 1636 42618444
Gastrointestinal ischaemia 39.41 23.70 7 1248 308 42619772
Wrong drug 36.62 23.70 6 1249 162 42619918
Shock haemorrhagic 24.01 23.70 11 1244 16231 42603849

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperaesthesia 75.28 23.03 27 4683 14700 110569889
Dental restoration failure 70.98 23.03 15 4695 1132 110583457
Limb injury 65.51 23.03 32 4678 37604 110546985
Angioplasty 62.89 23.03 15 4695 1956 110582633
Fall 62.15 23.03 100 4610 603382 109981207
Nasal discharge discolouration 60.41 23.03 16 4694 3185 110581404
Cardiac disorder 58.83 23.03 38 4672 76242 110508347
Haemorrhage 53.88 23.03 41 4669 106651 110477938
Peripheral vascular disorder 52.55 23.03 18 4692 8558 110576031
Transient ischaemic attack 52.13 23.03 33 4677 63949 110520640
Crepitations 48.44 23.03 18 4692 10817 110573772
Phlebitis 46.40 23.03 17 4693 9824 110574765
Fungal infection 45.92 23.03 28 4682 50778 110533811
Catheter site pain 45.31 23.03 15 4695 6431 110578158
Epigastric discomfort 44.09 23.03 16 4694 8999 110575590
Choking 42.64 23.03 18 4692 15092 110569497
Bradycardia 42.33 23.03 42 4668 155475 110429114
Splenic rupture 39.55 23.03 11 4699 2626 110581963
Glaucoma 38.73 23.03 19 4691 22498 110562091
Panic attack 37.00 23.03 20 4690 28920 110555669
Hypersensitivity 36.20 23.03 63 4647 403935 110180654
Encephalitis 35.74 23.03 17 4693 18822 110565767
Sputum discoloured 34.86 23.03 19 4691 27926 110556663
Eye irritation 34.30 23.03 20 4690 33432 110551157
Gastrointestinal ischaemia 33.04 23.03 7 4703 534 110584055
Stevens-Johnson syndrome 32.82 23.03 22 4688 46879 110537710
Status epilepticus 32.70 23.03 19 4691 31552 110553037
Coma 32.37 23.03 32 4678 117837 110466752
Middle insomnia 31.43 23.03 16 4694 20486 110564103
Pulmonary congestion 30.39 23.03 18 4692 30948 110553641
Vascular resistance systemic 30.03 23.03 4 4706 15 110584574
Cardiac failure congestive 29.13 23.03 34 4676 150966 110433623
Poor venous access 28.74 23.03 16 4694 24506 110560083
Wrong drug 28.49 23.03 6 4704 445 110584144
Ischaemic stroke 28.02 23.03 19 4691 41244 110543345
Urinary retention 27.11 23.03 23 4687 69660 110514929
Skin laceration 26.46 23.03 17 4693 33736 110550853
Sopor 25.23 23.03 17 4693 36529 110548060

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AB05 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, selective
ATC S01ED02 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Beta blocking agents
ATC S01ED52 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Beta blocking agents
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
CHEBI has role CHEBI:35530 ฮฒ-adrenergic antagonist
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:66991 sympatholytic agent
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013565 Sympatholytics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D058671 Adrenergic beta-1 Receptor Antagonists

Related Drugs by ATC class:

C07AB Beta blocking agents, selective 13 drugs
acebutololatenololbevantololbisoprololceliprololepanololesatenololesmolollandiololmetoprololnebivololpractolol show all 13 →
S01ED Beta blocking agents 5 drugs
befunololcarteolollevobunololmetipranololtimolol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Hypertensive disorder indication 38341003 DOID:10763
Open-angle glaucoma indication 84494001 DOID:1067
Malignant glaucoma off-label use 10100008
Aphakic glaucoma off-label use 15374009
Secondary glaucoma off-label use 95717004
Bronchospasm contraindication 4386001
Psoriasis contraindication 9014002 DOID:8893
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Depressive disorder contraindication 35489007
Anaphylaxis contraindication 39579001
Chronic heart failure contraindication 48447003
Sinus bradycardia contraindication 49710005
Acute nephropathy contraindication 58574008
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Asthma contraindication 195967001 DOID:2841
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Pheochromocytoma contraindication 302835009
Acute exacerbation of asthma contraindication 708038006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Kd 8.80 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 7.20 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.61 CHEMBL
Transmembrane protein 97 Enzyme Ki 5.78 CHEMBL
Beta-2 adrenergic receptor GPCR Kd 6.98 CHEMBL
Beta-2 adrenergic receptor GPCR IC50 6.18 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 8.53 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 8.76 CHEMBL

External reference:

IDSource
4019633 VUID
N0000147726 NUI
D00598 KEGG_DRUG
63659-19-8 SECONDARY_CAS_RN
142144 RXNORM
C0005320 UMLSCUI
CHEBI:3082 CHEBI
CHEMBL423 ChEMBL_ID
CHEMBL1691 ChEMBL_ID
DB00195 DRUGBANK_ID
D015784 MESH_DESCRIPTOR_UI
2369 PUBCHEM_CID
549 IUPHAR_LIGAND_ID
4530 INN_ID
O0ZR1R6RZ2 UNII
31545 MMSL
4280 MMSL
d00176 MMSL
4018588 VANDF
4019633 VANDF
001859 NDDF
004743 NDDF
349900007 SNOMEDCT_US
387195001 SNOMEDCT_US
409276006 SNOMEDCT_US
O0ZR1R6RZ2 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Betoptic S HUMAN PRESCRIPTION DRUG LABEL 1 0078-0729 SUSPENSION/ DROPS 2.80 mg OPHTHALMIC NDA 25 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-623 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-624 TABLET, FILM COATED 20 mg ORAL ANDA 19 sections
BETAXOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10702-013 TABLET, COATED 10 mg ORAL ANDA 12 sections
BETAXOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10702-014 TABLET, COATED 20 mg ORAL ANDA 12 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 17478-705 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 19 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 24658-700 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 24658-701 TABLET, FILM COATED 20 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 42806-038 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 42806-039 TABLET, FILM COATED 20 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 54868-4932 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Betaxolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 61314-245 SOLUTION/ DROPS 5.60 mg OPHTHALMIC NDA authorized generic 19 sections